A Practitioner’s Guide to Prescribing Tiagabine for Adults with Intellectual Disabilities

  • Jose de Leon
Chapter

Abstract

We developed this tiagabine guideline using drug prescribing information and reviewing the available literature on relevant neuropsychiatric disorders in populations without intellectual disabilities because of the dearth of available literature on the population with intellectual disabilities. This guideline includes indications; contraindications; assessments prior to and during treatment; dosing with particular focus on dosing modifications required by drug–drug interactions, personal characteristics; and adverse drug reactions. The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available; thus, there will be a need to periodically update this guideline as new information becomes available. Nevertheless, we believe that this guideline provides a useful resource for clinicians who treat epilepsy in adult individuals with intellectual disabilities. A tiagabine drug utilization review that summarizes this guideline is described.

Keywords

Carbamazepine Erythromycin Fluoxetine Fluconazole Dystonia 

References

  1. Adkins, J. C., & Noble, S. (1998). Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs, 55, 437–460.PubMedCrossRefGoogle Scholar
  2. Aikiä, M., Jutila, L., Salmenperä, T., Mervaala, E., & Kälviäinen, R. (2006). Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy. Epilepsy & Behavior, 8, 750–755.CrossRefGoogle Scholar
  3. Bauer, J., Bergmann, A., Reuber, M., Stodieck, S. R., & Genton, P. (2002). Tolerability of tiagabine: A prospective open-label study. Epileptic Disorders, 4, 257–260.PubMedGoogle Scholar
  4. Bell, G. S., Mula, M., & Sander, J. W. (2009). Suicidality in people taking antiepileptic drugs: What is the evidence? CNS Drugs, 23, 281–292.PubMedCrossRefGoogle Scholar
  5. Bockbrader, H. N., Burger, P., & Knapp, L. (2011). Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia, 52, 405–409.PubMedGoogle Scholar
  6. Burstein, A. H., Boudreau, E. A., & Theodore, W. H. (2009). Increase in tiagabine serum concentration with coadministration of gemfibrozil. The Annals of Pharmacotherapy, 43, 379–382.PubMedGoogle Scholar
  7. Inc, C. (2010). Gabitril-tiagabine hydrochloride tablet (prescribing information). Frazer, PA: Cephalon Inc.Google Scholar
  8. Chmielewska, B., & Stelmasiak, Z. (2002). Effectiveness of adjunctive therapy with tiagabine in mentally disabled patients with epilepsy. Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina, 57, 226–236.Google Scholar
  9. Crawford, P., Meinardi, H., Brown, S., Rentmeester, T. W., Pedersen, B., Pedersen, P. C., et al. (2001). Tiagabine: Efficacy and safety in adjunctive treatment of partial seizures. Epilepsia, 42, 531–538.PubMedCrossRefGoogle Scholar
  10. Davidson, J. R., Brady, K., Mellman, T. A., Stein, M. B., & Pollack, M. H. (2007). The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology, 27, 85–88.PubMedCrossRefGoogle Scholar
  11. de Borchgrave, V., Lienard, F., Willemart, T., & van Rijckevorsel, K. (2003). Clinical and EEG findings in six patients with altered mental status receiving tiagabine therapy. Epilepsy & Behavior, 4, 326–37.CrossRefGoogle Scholar
  12. Flowers, C. M., Racoosin, J. A., & Kortepeter, C. (2006). Seizure activity and off-label use of tiagabine. The New England Journal of Medicine, 354, 773–734.PubMedCrossRefGoogle Scholar
  13. Fulton, J. A., Hoffman, R. S., & Nelson, L. S. (2005). Tiagabine overdose: A case of status epilepticus in a non-epileptic patient. Clinical Toxicology, 43, 869–871.PubMedCrossRefGoogle Scholar
  14. Genton, P., Guerrini, R., & Perucca, E. (2001). Tiagabine in clinical practice. Epilepsia, 42(Suppl 3), 42–45.PubMedCrossRefGoogle Scholar
  15. Hachad, H., Ragueneau-Majlessi, I., & Levy, R. H. (2002). New antiepileptic drugs: Review on drug interactions. Therapeutic Drug Monitoring, 24, 91–103.PubMedCrossRefGoogle Scholar
  16. Harris, E. C., & Barraclough, B. (1997). Suicide as an outcome for mental disorders. A meta-analysis. The British Journal of Psychiatry, 170, 205–228.PubMedCrossRefGoogle Scholar
  17. Hesdorffer, D. C., Berg, A. T., & Kanner, A. M. (2010). An update on antiepileptic drugs and suicide: Are there definitive answers yet? Epilepsy Current, 10, 137–145.CrossRefGoogle Scholar
  18. Johannessen, S. I., & Tomson, T. (2006). Pharmacokinetic variability of newer antiepileptic drugs. When is monitoring needed? Clinical Pharmacokinetics, 45, 1061–1075.PubMedCrossRefGoogle Scholar
  19. Kalanin, V. V. (2007). Suicidality and antiepileptic drugs. Is there a link? Drug Safety, 30, 123–142.CrossRefGoogle Scholar
  20. Kälviäinen, R. (1998). Tiagabine: A new therapeutic option for people with intellectual disability and partial epilepsy. Journal of Intellectual Disability Research, 42(Suppl 1), 63–67.PubMedGoogle Scholar
  21. Kälviäinen, R. (2001). Long-term safety of tiagabine. Epilepsia, 42(Suppl 3), 46–48.PubMedCrossRefGoogle Scholar
  22. Kastberg, H., Jansen, J. A., Cole, G., & Wesnes, K. (1998). Tiagabine: Absence of kinetic or dynamic interactions with ethanol. Drug Metabolism and Drug Interactions, 14, 259–273.PubMedCrossRefGoogle Scholar
  23. Kellinghaus, C., Dziewas, R., & Lüdemann, P. (2002). Tiagabine-related non-convulsive status epilepticus in partial epilepsy: Three case reports and a review of the literature. Seizure, 11, 243–249.PubMedCrossRefGoogle Scholar
  24. Koepp, M. J., Edwards, M., Collins, J., Farrel, F., & Smith, S. (2005). Status epilepticus and tiagabine therapy revisited. Epilepsia, 46, 1625–1632.PubMedCrossRefGoogle Scholar
  25. Kuehn, B. M. (2008). FDA warns of adverse events linked to smoking cessation drug and antiepileptics. The Journal of the American Medical Association, 299, 1121–1122.CrossRefGoogle Scholar
  26. Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). Drug information handbook (18th ed.). Hudson, OH: Lexi-Comp Inc.Google Scholar
  27. Leach, J. P., & Brodie, M. J. (1998). Tiagabine. Lancet, 351, 203–207.PubMedCrossRefGoogle Scholar
  28. Merrick, J., Merrick, E., Lunsky, Y., & Kandel, I. (2006). A review of suicidality in persons with intellectual disability. The Israel Journal of Psychiatry and Related Science, 43, 258–264.Google Scholar
  29. Mula, M., Pini, S., & Cassano, G. B. (2007). The role of anticonvulsant drugs in anxiety disorders: A critical review of the evidence. Journal of Clinical Psychopharmacology, 27, 263–272.PubMedCrossRefGoogle Scholar
  30. Mula, M., & Sander, J. W. (2007). Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Safety, 30, 555–567.PubMedCrossRefGoogle Scholar
  31. Pereira, J., Marson, A. G., Hutton, J. L. (2002). Tiagabine add-on for drug-resistant partial epilepsy. The Cochrane Database Systematic Review 3:CD001908.Google Scholar
  32. Pollack, M. H., Tiller, J., Xie, F., & Trivedi, M. H. (2008). Tiagabine in adult patients with generalized anxiety disorder: Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Journal of Clinical Psychopharmacology, 28, 308–316.PubMedCrossRefGoogle Scholar
  33. Richens, A., Marshall, R. W., Dirach, J., Jansen, J. A., Snel, S., & Pedersen, P. C. (1998). Absence of interaction between tiagabine, a new antiepileptic drug, and the benzodiazepine triazolam. Drug Metabolism and Drug Interactions, 14, 159–177.PubMedCrossRefGoogle Scholar
  34. Sackellares, J. C., Krauss, G., Sommerville, K. W., & Deaton, R. (2002). Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia, 43, 394–398.PubMedCrossRefGoogle Scholar
  35. Schachter, S. C. (2001). Pharmacology and clinical experience with tiagabine. Expert Opinion on Pharmacotherapy, 2, 179–187.PubMedCrossRefGoogle Scholar
  36. Schmidt, D., Gram, L., Brodie, M., Krämer, G., Perucca, E., Kälviäinen, R., et al. (2000). Tiagabine in the treatment of epilepsy—A clinical review with a guide for the prescribing physician. Epilepsy Research, 41, 245–251.PubMedCrossRefGoogle Scholar
  37. Schwartz, T. L., & Nihalani, N. (2006). Tiagabine in anxiety disorders. Expert Opinion on Pharmacotherapy, 7, 1977–1987.PubMedCrossRefGoogle Scholar
  38. Shinnar, S., Berg, A. T., Treiman, D. M., Hauser, W. A., Hesdorffer, D. C., Sackellares, J. C., et al. (2001). Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons. Epilepsia, 42, 372–379.PubMedCrossRefGoogle Scholar
  39. Simister, R. J., Sander, J. W., & Koepp, M. J. (2007). Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy & Behavior, 2, 336–339.CrossRefGoogle Scholar
  40. Thomsen, M. S., Groes, L., Agersø, H., & Kruse, T. (1998). Lack of pharmacokinetic interaction between tiagabine and erythromycin. Journal of Clinical Pharmacology, 38, 1051–1056.CrossRefGoogle Scholar
  41. Tombini, M., Pacifici, L., Passarelli, F., & Rossini, P. M. (2006). Transient athetosis induced by tiagabine. Epilepsia, 47, 799–800.PubMedCrossRefGoogle Scholar
  42. US Department of Mental Health and Human Services. (2008). Statistical review and evaluation: Antiepileptic drugs and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf Accessed 5.04.2011.
  43. Weintraub, D., Buchsbaum, R., Resor, S. R., Jr., & Hirsch, L. J. (2007). Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior, 10, 105–110.CrossRefGoogle Scholar
  44. Wolańczyk, T., & Grabowska-Grzyb, A. (2001). Transient dystonias in three patients treated with tiagabine. Epilepsia, 42, 944–946.PubMedCrossRefGoogle Scholar
  45. Young, A. H., Geddes, J. R., Macritchie, K., Rao, S. N., Vasudev, A. (2006a). Tiagabine in the maintenance treatment of bipolar disorders. The Cochrane Database Systematic Review 3:CD005173.Google Scholar
  46. Young, A. H., Geddes, J. R., Macritchie, K., Rao, S. N., Vasudev, A. (2006b). Tiagabine in the treatment of acute affective episodes in bipolar disorder: Efficacy and acceptability. The Cochrane Database Systematic Review 3:CD004694.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jose de Leon
    • 1
  1. 1.Department of Psychiatry College of MedicineUniversity of KentuckyLexingtonUSA

Personalised recommendations